Theravance Biopharma (NASDAQ:TBPH) Lowered to “Buy” Rating by Wall Street Zen

Wall Street Zen downgraded shares of Theravance Biopharma (NASDAQ:TBPH) from a strong-buy rating to a buy rating in a research report sent to investors on Saturday.

TBPH has been the topic of several other research reports. BTIG Research raised their price objective on shares of Theravance Biopharma from $25.00 to $40.00 and gave the company a “buy” rating in a research report on Wednesday, November 26th. B. Riley started coverage on Theravance Biopharma in a research note on Friday, September 12th. They issued a “buy” rating and a $28.00 target price on the stock. Oppenheimer initiated coverage on Theravance Biopharma in a research report on Wednesday, December 3rd. They set an “outperform” rating and a $27.00 price target on the stock. Weiss Ratings reiterated a “hold (c)” rating on shares of Theravance Biopharma in a report on Wednesday, October 8th. Finally, Zacks Research cut Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a report on Monday, September 15th. Two investment analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $27.80.

Theravance Biopharma Stock Down 3.0%

NASDAQ:TBPH opened at $18.15 on Friday. The stock has a market cap of $919.66 million, a P/E ratio of 31.84 and a beta of 0.14. The business’s 50-day moving average price is $17.63 and its two-hundred day moving average price is $14.46. Theravance Biopharma has a twelve month low of $7.90 and a twelve month high of $20.33.

Theravance Biopharma (NASDAQ:TBPH) last posted its quarterly earnings data on Monday, November 10th. The biopharmaceutical company reported $0.07 earnings per share for the quarter, topping the consensus estimate of ($0.03) by $0.10. Theravance Biopharma had a net margin of 36.53% and a return on equity of 12.20%. The company had revenue of $19.99 million for the quarter, compared to analysts’ expectations of $19.89 million. On average, equities research analysts expect that Theravance Biopharma will post -1.09 EPS for the current fiscal year.

Insider Buying and Selling at Theravance Biopharma

In other news, SVP Rhonda Farnum sold 31,067 shares of the business’s stock in a transaction dated Wednesday, December 3rd. The stock was sold at an average price of $18.75, for a total value of $582,506.25. Following the completion of the sale, the senior vice president owned 277,695 shares of the company’s stock, valued at approximately $5,206,781.25. The trade was a 10.06% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 6.90% of the company’s stock.

Hedge Funds Weigh In On Theravance Biopharma

A number of large investors have recently bought and sold shares of the stock. Quarry LP purchased a new stake in shares of Theravance Biopharma during the third quarter valued at approximately $26,000. Caitong International Asset Management Co. Ltd raised its holdings in Theravance Biopharma by 107.4% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 2,725 shares of the biopharmaceutical company’s stock valued at $40,000 after buying an additional 1,411 shares during the last quarter. Tower Research Capital LLC TRC raised its holdings in Theravance Biopharma by 18.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company’s stock valued at $55,000 after buying an additional 781 shares during the last quarter. CIBC Private Wealth Group LLC boosted its position in Theravance Biopharma by 20,269.6% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 4,685 shares of the biopharmaceutical company’s stock valued at $68,000 after buying an additional 4,662 shares during the period. Finally, SG Americas Securities LLC bought a new stake in Theravance Biopharma in the 3rd quarter worth $101,000. 99.10% of the stock is owned by hedge funds and other institutional investors.

About Theravance Biopharma

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.